Ashok Kumar Jangid
Overview
Explore the profile of Ashok Kumar Jangid including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Noh K, Jangid A, Park J, Kim S, Kim K
J Mater Chem B
. 2024 Oct;
12(46):12087-12102.
PMID: 39465499
Although natural killer (NK) cell-based adoptive cell transfer (ACT) has shown promise in cancer immunotherapy, its efficacy against solid tumors is limited in the immunosuppressive tumor microenvironment (TME). Combinatorial therapies...
2.
Jangid A, Kim K
Adv Colloid Interface Sci
. 2024 Sep;
333:103301.
PMID: 39260104
Phenylboronic acid (PBA) is recognized as one of the most promising cancer cell binding modules attributed to its potential to form reversible and dynamic boronic ester covalent bonds. Exploring the...
3.
Jangid A, Kim S, Kim K
Int J Biol Macromol
. 2024 Jul;
275(Pt 2):133738.
PMID: 38992536
Pancreatic cancer cells highly resistance to conventional chemo drugs, resulting low survival rates. The aim of the study was to design and develop dual targeting polymersomes (DTPS) loaded with phyto...
4.
Jangid A, Noh K, Kim S, Kim K
Carbohydr Polym
. 2024 Jun;
340:122311.
PMID: 38858027
Modified biopolymers that are based on prebiotics have been found to significantly contribute to immunomodulatory events. In recent years, there has been a growing use of modified biomaterials and polymer-functionalized...
5.
Park H, Lee W, Kim S, Jangid A, Park J, Lee C, et al.
Biomacromolecules
. 2024 Feb;
25(3):1959-1971.
PMID: 38379131
Triple-negative breast cancer (TNBC) presents treatment challenges due to a lack of detectable surface receptors. Natural killer (NK) cell-based adaptive immunotherapy is a promising treatment because of the characteristic anticancer...
6.
Park J, Kim S, Jangid A, Park H, Kim K
Int J Mol Sci
. 2024 Feb;
25(3).
PMID: 38338836
Current cytokine-based natural killer (NK) cell priming techniques have exhibited limitations such as the deactivation of biological signaling molecules and subsequent insufficient maturation of the cell population during mass cultivation...
7.
Kim S, Li S, Jangid A, Park H, Lee D, Jung H, et al.
Small
. 2023 Dec;
20(24):e2306738.
PMID: 38161257
Adoptive immunotherapy utilizing natural killer (NK) cells has demonstrated remarkable efficacy in treating hematologic malignancies. However, its clinical intervention for solid tumors is hindered by the limited expression of tumor-specific...
8.
Jangid A, Kim S, Park H, Kim H, Kim K
Biomacromolecules
. 2023 Dec;
25(1):222-237.
PMID: 38130077
Phenylboronic acid (PBA) has been highly acknowledged as a significant cancer recognition moiety in sialic acid-overexpressing cancer cells. In this investigation, lipid-mediated biomaterial integrated PBA molecules onto the surface of...
9.
Jain P, Jangid A, Pooja D, Kulhari H
J Mater Chem B
. 2023 Dec;
12(3):577-608.
PMID: 38116805
In the past few years, manganese-based nanostructures have been extensively investigated in the biomedical field particularly to design highly biocompatible theranostics, which can not only act as efficient diagnostic imaging...
10.
Lee C, Kim S, Park H, Lee W, Jangid A, Choi Y, et al.
Nano Converg
. 2023 Dec;
10(1):56.
PMID: 38097911
Natural killer (NK) cells have clinical advantages in adoptive cell therapy owing to their inherent anticancer efficacy and their ability to identify and eliminate malignant tumors. However, insufficient cancer-targeting ligands...